AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy was estimated to be worth US$ 767 million in 2023 and is forecast to a readjusted size of US$ 1106.4 million by 2030 with a CAGR of 5.4% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by region & country, by Type, and by Application.
The Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
Market Segmentation
By Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Segment by Type:
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Segment by Application
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
1.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends & Drivers
1.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
1.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers & Opportunity
1.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
1.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Revenue Ranking (2023)
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Company (2019-2024)
2.3 Key Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
2.6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Analysis
2.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Single-stranded AAV (ssAAV)
3.1.2 Self-complementary AAV (scAAV)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type
3.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, by Type (2019-2030)
3.2.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hemophilia
4.1.2 Ophthalmology
4.1.3 Lysosomal Storage Disorders
4.1.4 Neurological Disorders
4.1.5 Others
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application
4.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, by Application (2019-2030)
4.2.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Region
5.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Region (2019-2024)
5.1.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Region (2025-2030)
5.1.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
5.2.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
5.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
5.4.2 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
5.5.2 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
5.6.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value
6.3 United States
6.3.1 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.3.2 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.5.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.6.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.7.2 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.8.2 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value, 2019-2030
6.9.2 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 BioMarin Pharmaceutical
7.1.1 BioMarin Pharmaceutical Profile
7.1.2 BioMarin Pharmaceutical Main Business
7.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.1.5 BioMarin Pharmaceutical Recent Developments
7.2 Sangamo Therapeutics
7.2.1 Sangamo Therapeutics Profile
7.2.2 Sangamo Therapeutics Main Business
7.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.2.5 Sangamo Therapeutics Recent Developments
7.3 Amicus Therapeutics
7.3.1 Amicus Therapeutics Profile
7.3.2 Amicus Therapeutics Main Business
7.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.3.5 Roche Recent Developments
7.4 Roche
7.4.1 Roche Profile
7.4.2 Roche Main Business
7.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.4.5 Roche Recent Developments
7.5 Pfizer
7.5.1 Pfizer Profile
7.5.2 Pfizer Main Business
7.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.5.5 Pfizer Recent Developments
7.6 NightstaRx
7.6.1 NightstaRx Profile
7.6.2 NightstaRx Main Business
7.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.6.5 NightstaRx Recent Developments
7.7 MeiraGTx
7.7.1 MeiraGTx Profile
7.7.2 MeiraGTx Main Business
7.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.7.5 MeiraGTx Recent Developments
7.8 Sarepta Therapeutics
7.8.1 Sarepta Therapeutics Profile
7.8.2 Sarepta Therapeutics Main Business
7.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.8.5 Sarepta Therapeutics Recent Developments
7.9 Neurocrine Biosciences
7.9.1 Neurocrine Biosciences Profile
7.9.2 Neurocrine Biosciences Main Business
7.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.9.5 Neurocrine Biosciences Recent Developments
7.10 Voyager Therapeutics
7.10.1 Voyager Therapeutics Profile
7.10.2 Voyager Therapeutics Main Business
7.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.10.5 Voyager Therapeutics Recent Developments
7.11 Asklepios Biopharmaceutical
7.11.1 Asklepios Biopharmaceutical Profile
7.11.2 Asklepios Biopharmaceutical Main Business
7.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
7.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2019-2024)
7.11.5 Asklepios Biopharmaceutical Recent Developments
8 Industry Chain Analysis
8.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industrial Chain
8.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
听
听
*If Applicable.